CSIMarket
 


Nanoviricides inc   (NNVC)
Other Ticker:  
 

Cumulative Nanoviricides Inc 's Working Capital Ratio for Trailing Twelve Months Period

NNVC's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

NNVC Working Capital Ratio for Trailing Twelve Months Period

(Dec 31 2023)
II. Quarter
(Sep 30 2023)
I. Quarter
(Jun 30 2023)
IV. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
II. Quarter
Y / Y Current Liabilities Growth 104.71 % 82.93 % 29.43 % -9.83 % 34.94 %
Y / Y Current Assets Growth -53.97 % -45.69 % -41.43 % -37.74 % -34.05 %
Working Capital Ratio for Trailing Twelve Months Period 11.08 16.15 23.09 28.12 30.9
Total Ranking # 106 # 132 # 70 # 56 # 49
Seq. Current Liabilities Growth 0.3 % 77.48 % 53.23 % -24.95 % -10.38 %
Seq. Current Assets Growth -25.55 % -15.42 % -14.96 % -14.04 % -12.17 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Due to rise in Current Liabilities in the II. Quarter to $1 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 11.08 below Nanoviricides Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 83 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Nanoviricides Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about NNVC
Working Capital Ratio NNVC in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 84
Sector # 166
S&P 500 # 304


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
38.01 14.71 0.97
(Mar 31 2022)   (Dec 31 2019)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Morphic Holding inc   30.36 
Inhibitor Therapeutics Inc   30.12 
Ars Pharmaceuticals Inc   29.84 
Design Therapeutics Inc   29.45 
Cohbar Inc   28.02 
Cyteir Therapeutics Inc   27.43 
Atossa Therapeutics Inc   27.33 
Eliem Therapeutics Inc   26.96 
Gh Research Plc  26.81 
Theseus Pharmaceuticals Inc   26.42 
Briacell Therapeutics Corp   26.40 
Terns Pharmaceuticals Inc   26.18 
Acelyrin Inc   25.54 
Astria Therapeutics inc   24.70 
Bright Minds Biosciences Inc   24.26 
Belite Bio Inc  24.04 
Xenon Pharmaceuticals Inc   23.80 
Eqrx Inc   23.53 
Aprea Therapeutics Inc   23.32 
Mineralys Therapeutics Inc   22.84 
Lixte Biotechnology Holdings Inc   22.42 
Sio Gene Therapies Inc   21.97 
Janux Therapeutics Inc   21.43 
Pmv Pharmaceuticals Inc   21.33 
Savara Inc   21.10 
Edgewise Therapeutics inc   21.08 
Nuvalent Inc   20.64 
Lantern Pharma Inc   20.56 
Kura Oncology Inc   20.51 
Akero Therapeutics Inc   19.91 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com